Multiple inflammatory and immune signaling proteins

Multiple inflammatory and immune signaling proteins refers to a broad category of molecular entities, including cytokines, chemokines, and intracellular signaling enzymes, that orchestrate the body's immune and inflammatory responses [1]. This group encompasses well-known targets such as Tumor Necrosis Factor (TNF), Interleukins (e.g., IL-1, IL-6, IL-17), and the Janus Kinase (JAK) family of proteins [2, 3]. These proteins function in complex, overlapping networks to regulate cell activation, proliferation, and the recruitment of immune cells to sites of injury or infection [1]. Dysregulation of these signaling pathways is a primary driver of chronic inflammatory conditions, autoimmune diseases, and systemic inflammatory response syndromes [2]. Therapeutic intervention often involves the use of broad-spectrum agents like corticosteroids, which modulate the expression of numerous inflammatory genes, or more targeted therapies like JAK inhibitors and biologics that interrupt specific signaling nodes [3, 4]. While effective in treating disease, the systemic inhibition of these proteins can lead to significant safety concerns, primarily an increased risk of serious infections due to suppressed host defense mechanisms [3, 4].

Other names

Inflammatory mediatorsImmune signaling moleculesPro-inflammatory proteinsCytokine signaling network

Drugs targeting these proteins typically function by inhibiting the production, signaling, or activity of multiple mediators. Corticosteroids (e.g., dexamethasone) act via the glucocorticoid receptor to inhibit the transcription of pro-inflammatory cytokines [4]. Small molecule inhibitors like JAK inhibitors (e.g., tofacitinib) block the intracellular signaling pathways shared by various cytokine receptors, thereby preventing the activation of downstream transcription factors [3]. Biologic agents provide targeted neutralization of specific cytokines or their receptors to interrupt the inflammatory cascade [2].